KPTI - Karyopharm: Strong Potential Low Price Looks Investible February, 07 2021 08:00 AM Karyopharm Therapeutics Inc. KPTI is doing well with selinexor, with additional approvals and increasing sales. There are additional label expansions in the offing. The stock seems undervalued at current prices. For further details see: Karyopharm: Strong Potential, Low Price, Looks Investible